A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1339-1344

  Renouf, Daniel J ^a   Welch, Stephen ^b   Moore, Malcolm J ^c   Krzyzanowska, Monika K ^c   Knox, Jennifer ^c   Feld, Ronald ^c   Liu, Geo Vrey ^c   MacKay, Helen ^c   Petronis, Jennifer ^c   Wang, Lisa ^c   Chen, Eric ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bevacizumab; Capecitabine; Colorectal cancer; Irinotecan; Phase II

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANAL EXAMINATION; ANOREXIA; ARTICLE; CANCER CONTROL; COLORECTAL CANCER; COLORECTAL METASTASIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM EXAMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOSIS; WEIGHT CHANGE; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84862293013     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1843-9     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96 (Pubitemid 351521864)
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581-592 (Pubitemid 46359643)
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, Xuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342 (Pubitemid 38702844)
4. Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB III et al (2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-Xuorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17(9):1399-1403 (Pubitemid 44400378)
5. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, Xuorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539-1544 (Pubitemid 46733080)
6. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as Wrst-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013-2019
7. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E et al (2008) Bevacizumab beyond Wrst progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326-5334
8. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibartolomeo M et al (2009) Safety and eYcacy of Wrst-line bevacizumab with FOLFOX, XELOX, FOLFIRI and Xuoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842-1847
9. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23(22):4866-4875 (Pubitemid 46223991)
10. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and Xuorouracil with or without oxaliplatin as Wrst-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938-2947 (Pubitemid 30644117)
11. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al (2000) Irinotecan combined with Xuorouracil compared with Xuorouracil alone as Wrst-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041-1047 (Pubitemid 30162806)
12. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated Xuorouracil-leucovorin as Wrst-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136-147 (Pubitemid 30036347)
13. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-SeraW M, Lutz MP et al (2005) Phase III study of weekly high-dose infusional Xuorouracil plus folinic acid with or without irinotecan in patientswith metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23(22):4856-4865 (Pubitemid 46223990)
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus Xuorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905-914
15. Sorbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M et al (2004) Multicenter phase II study of Nordic Xuorouracil and folinic acid bolus schedule combined with oxaliplatin as Wrst-line treatment of metastatic colorectal cancer. J Clin Oncol 22(1):31-38 (Pubitemid 41095111)
16. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040-2048 (Pubitemid 350106711)
17. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658-1664 (Pubitemid 46797944)
18. Cassidy J, Twelves C, Van Cutsem E, HoV P, Bajetta E, Boyer M et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-Xuorouracil/leucovorin. Ann Oncol 13(4):566-575 (Pubitemid 34461140)
19. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C et al (2001) Capecitabine (Xeloda) improves medical resource use compared with 5-Xuorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37(5):597-604 (Pubitemid 32261017)
20. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M et al (2001) Oral capecitabine compared with intravenous Xuorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097-4106 (Pubitemid 33049527)
21. Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR (2004) Cost-benefit analysis of capecitabine versus 5-Xuorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 26(4):579-589 (Pubitemid 38586459)
22. Czejka M, Schueller J, Hauer K, Ostermann E (2005) Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer. Anticancer Res 25(4):2985-2990 (Pubitemid 41044691)
23. Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T et al (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as Wrst-line therapy for advanced colorectal cancer. Ann Oncol 16(7):1123-1132 (Pubitemid 41418315)
24. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S et al (2004) Randomized multicenter Phase II trial of two diVerent schedules of irinotecan combined with capecitabine as Wrst-line treatment in metastatic colorectal carcinoma. Cancer 100(2):279-287 (Pubitemid 38063635)
25. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P et al (2005) A randomized phase II trial of capecitabine and two diVerent schedules of irinotecan in Wrst-line treatment of metastatic colorectal cancer: eYcacy, quality-of-life and toxicity. Ann Oncol 16(2):282-288 (Pubitemid 40309311)
26. Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA, Asmar L (2005) Results of a phase II open-label study of capecitabine in combination with irinotecan as Wrst-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5(1):50-56
27. Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS et al (2005) Multicenter phase II study of oral capecitabine plus irinotecan as Wrst-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta Oncol 44(3):230-235 (Pubitemid 40904125)
28. Park SH, Bang SM, Cho EK, Baek JH, Oh JH, Im SA et al (2004) First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 66(5):353-357 (Pubitemid 39194356)
29. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, JeVery M et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral Xuoropyrimidines in Wrst-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25(30):4779-4786 (Pubitemid 350086481)
30. Kohne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K et al (2008) Irinotecan combined with infusional 5-Xuorouracil/ folinic acid or capecitabine plus celecoxib or placebo in the Wrstline treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19(5):920-926 (Pubitemid 351627308)
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
32. Garcia-Alfonso P, Munoz-Martin AJ, Alvarez-Suarez S, Jerez-Gilarranz Y, Riesco-Martinez M, Khosravi P et al (2010) Bevacizumab in combination with biweekly capecitabine and irinotecan, as Wrst-line treatment for patients with metastatic colorectal cancer. Br J Cancer 103(10):1524-1528
33. Ducreux M, Adenis A, Mendiboure E et al (2009) EYcacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV+FOLFIRI versus BEV+XELIRI (FNCLCC ACCORD 13/0503 study). J Clin Oncol 27:15s
34. Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J et al (2009) Phase IV study of bevacizumab in combination with infusional Xuorouracil, leucovorin and irinotecan (FOLFIRI) in Wrst-line metastatic colorectal cancer. Oncology 77(2):113-119